[BIOSTAR PHARMACEUTICALS, INC. TO PRESENT AT THE BREAN MURRAY, CARRET & CO. CHINA GROWTH CONFERENCE Press Release Source: Biostar Pharmaceuticals, Inc. On 8:00 am EST, Wednesday November 4, 2009 BSPM News ; XIANYANG, China, Nov. 4 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: Mr. Ronghua Wang, Chief Executive Officer and Ms. Elaine Zhao, Chief Financial Officer, are scheduled to] [BIOSTAR PHARMACEUTICALS ANNOUNCES CLOSING OF A $3.6 MILLION EQUITY FINANCING Press Release Source: Biostar Pharmaceuticals, Inc. On 8:00 am EST, Friday November 6, 2009 BSPM News ; XIANYANG, China, Nov. 6 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: After completing this transaction, Biostar has approximately 26.1 million shares outstanding on a diluted basis. "After evaluating several financing options to] [BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 THIRD QUARTER EARNINGS CONFERENCE CALL ON THURSDAY, NOVEMBER 12, 2009 AT 9:30 A.M. ET Press Release Source: Biostar Pharmaceuticals, Inc. On 8:00 am EST, Monday November 9, 2009 BSPM News ; XIANYANG, China, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: http://www.viavid.net http://viavid.net/dce.aspx?sid=00006CE5 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast]

[ARTICLES SUPPLEMENTARY TO THE ARTICLES OF INCORPOATION OF BIOSTAR PHARMACEUTICALS, INC. Biostar Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Maryland (the “Corporation”), hereby certifies to the State Department of Assessments and Taxation of Maryland, that: Annex A SECOND: A description of the shares so classified with the preferences, conversions and other rights, voting] [--------------------------------------- BIOSTAR PHARMACEUTICALS, INC. Number of Shares: Holder: Exercise Price per Share: $3.00 Company Purchase Agreement Common Stock Exercise Price Expiration Date The Company hereby certifies that, for value received, __________, or registered assigns (the “ 1. . 2. Investment Representation . Person 3. . 4. a. b. 5. a. b. Date of Exercise A “ c. d. Net Number] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers Parties Party BACKGROUND WHEREAS 1933 Act Regulation D SEC WHEREAS Series B Preferred Stock Common Stock Securities WHEREAS Escrow Agent Closing Escrow Agreement WHEREAS Make Good Escrow Agent Make Good Escrow Agreement WHEREAS NOW, THEREFORE Article 1 INCORPORATION BY REFERENCE AND DEFINITIONS 1.1 Incorporation by Reference 1.2 Supersedes Other Agreements] [MAKE GOOD ESCROW AGREEMENT Agreement Company Purchasers Purchaser Escrow Agent Escrowing Parties This Agreement, dated as of November 2, 2009 (this “ WITNESSETH: WHEREAS Purchase Agreement ) Series B Preferred Stock Common Stock Securities Purchase Price WHEREAS WHEREAS NOW, THEREFORE, in consideration of the mutual promises herein contained and intending to be legally bound, the parties hereby agree as follows:] [CLOSING ESCROW AGREEMENT Agreement Company Purchasers Purchaser Escrow Agent Escrowing Parties This Agreement, dated as of November 2, 2009 (this “ WITNESSETH: WHEREAS Purchase Agreement ) Series B Preferred Stock Common Stock Securities Purchase Price WHEREAS Escrowed Funds WHEREAS NOW, THEREFORE, in consideration of the mutual promises herein contained and intending to be legally bound, the parties hereby agree as]

[BIOSTAR PHARMACEUTICALS, INC. RECEIVES PATENT FOR AOXING GANBAO Press Release Source: Biostar Pharmaceuticals, Inc. On Friday October 2, 2009, 8:00 am EDT BSPM News ; XIANYANG, China, Oct. 2 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: Aoxing Ganbao is a traditional Chinese herbal product that is complementary for its flagship Xin Aoxing Oleanolic Acid Capsule to treat Hepatitis B.]

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL RESULTS Second Quarter 2009 Revenue Increased 40.6% to Approximately $13.2 Million and Net Income Increased 119.3% to Approximately $3.9 Million with EPS of $0.17 Gross Margins Improved 1630-Basis Points to 73.5% over Q2 2008 Press Release Source: Biostar Pharmaceuticals, Inc. On Friday August 14, 2009, 7:30 am EDT BSPM News ; XIANYANG,] [BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 SECOND QUARTER EARNINGS CONFERENCE CALL ON FRIDAY, AUGUST 14, 2009 AT 10:30 A.M. EDT Press Release Source: Biostar Pharmaceuticals, Inc. On Wednesday August 12, 2009, 7:30 am EDT BSPM News ; XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: http://www.viavid.net http://viavid.net/dce.aspx?sid=00006906 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast]